Shares of ELEKTA AB/ADR (OTCMKTS:EKTAY) hit a new 52-week high during trading on Thursday . The stock traded as high as $14.76 and last traded at $14.75, with a volume of 1558 shares trading hands. The stock had previously closed at $14.64.

Several brokerages recently commented on EKTAY. Zacks Investment Research raised ELEKTA AB/ADR from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research note on Wednesday, October 23rd. ValuEngine lowered ELEKTA AB/ADR from a “hold” rating to a “sell” rating in a research note on Thursday.

The company has a debt-to-equity ratio of 0.46, a current ratio of 1.08 and a quick ratio of 0.86. The company has a market cap of $5.60 billion, a price-to-earnings ratio of 44.70, a price-to-earnings-growth ratio of 2.87 and a beta of 0.46. The business has a 50 day simple moving average of $13.29 and a 200 day simple moving average of $13.14.


Elekta AB (publ) provides equipment and software for cancer and brain disorders worldwide. The company offers radiotherapy systems under the Versa HD, Precise Treatment System, and Elekta Compact names; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT.

See Also: Tariff

Receive News & Ratings for ELEKTA AB/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ELEKTA AB/ADR and related companies with's FREE daily email newsletter.